PhaseRx Inc. (PZRX) Trade Alert

Traders Circulating Community Register from European Commission for PhaseRX’s Treatment for Ornithine Transcarbamylase Deficiency.

The company has yet to issue a press release.

Long this name at $1.43.

PZRX came public 11 months ago at a price of $5.00.

Buyers at this level are getting a huge discount to IPO participants.